Payment Policy: Clinical Validation of Modifer 25 Reference Number: CC.PP.013 Product Types: ALL

Similar documents
Payment Policy: New Patient Reference Number: CC.PP.036 Product Types: ALL

Payment Policy:Modifier to Procedure Code Validation: Payment Modifiers Reference Number: CC.PP.028

Payment Policy: Unbundled Professional Services Reference Number: CC.PP.043 Product Types: ALL

Payment Policy: Unbundled Surgical Procedures Reference Number: CC.PP.045 Product Types: ALL

Payment Policy: Code Editing Overview Reference Number: CC.PP.011 Product Types: ALL Effective Date: 01/01/2013 Last Review Date: 06/28/2018

Payment Policy: Leveling of Emergency Room Services Reference Number: TX.PP.053 Product Types: ALL

Payment Policy: Status B Bundled Services Reference Number: CC.PP.046 Product Types: ALL

Clinical Policy: Brand Name Override Reference Number: CP.PMN.22 Effective Date: Last Review Date: 02.18

Moda Health Reimbursement Policy Overview

Profilnine is indicated for: Prevention and control of bleeding in patients with factor IX deficiency (hemophilia B).

Clinical Policy: Sodium phenylbutyrate (Buphenyl) Reference Number: CP.PHAR.208

Clinical Policy: Cabozantinib (Cometriq, Cabometyx) Reference Number: CP.PHAR.111

See Important Reminder at the end of this policy for important regulatory and legal information.

Clinical Policy: Request for Medically Necessary Drug Not on the PDL Reference Number: CP.PMN.16 Effective Date: Last Review Date: 11.

Clinical Policy: Factor VIIa (Recombinant - NovoSeven RT) Reference Number: CP.PHAR.220

Clinical Policy: Eltrombopag (Promacta) Reference Number: CP.PHAR.180

Clinical Policy: Belatacept (Nulojix) Reference Number: CP.PHAR.201 Effective Date: Last Review Date: Line of Business: Medicaid

Coding Implications Revision Log. See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information.

Clinical Policy: Irinotecan Liposome (Onivyde) Reference Number: CP.PHAR.304 Effective Date: Last Review Date: 11.18

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information.

Clinical Policy: Pralatrexate (Folotyn) Reference Number: CP.PHAR.313 Effective Date: Last Review Date: 11.18

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information.

Description Irinotecan liposome injection (Onivyde ) is a topoisomerase inhibitor.

Coding Implications Revision Log. See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information.

Clinical Policy: Eliglustat (Cerdelga) Reference Number: CP.PHAR.153 Effective Date: 02/16

Clinical Policy: Cabazitaxel (Jevtana) Reference Number: CP.PHAR.316 Effective Date: Last Review Date: Line of Business: Medicaid

Medically Unlikely Edits (MUE)

Clinical Policy: Paricalcitol Injection (Zemplar) Reference Number: CP.PHAR.270

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information.

Medically Unlikely Edits (MUE)

See Important Reminder at the end of this policy for important regulatory and legal information.

Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information.

Clinical Policy: Temsirolimus (Torisel) Reference Number: CP.PHAR.324 Effective Date: Last Review Date: Line of Business: HIM, Medicaid

See Important Reminder at the end of this policy for important regulatory and legal information.

Clinical Policy: Ibandronate Oral (Boniva) Reference Number: CP.PMN.96 Effective Date: Last Review Date: 02.19

See Important Reminder at the end of this policy for important regulatory and legal information.

Clinical Policy: Belatacept (Nulojix) Reference Number: CP.PHAR.201 Effective Date: Last Review Date: 11.18

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information.

Clinical Policy: Ofatumumab (Arzerra) Reference Number: CP.PHAR.306 Effective Date: Last Review Date: Line of Business: HIM, Medicaid

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information.

Clinical Policy: Ruxolitinib (Jakafi)

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information.

Injection and Infusion Services Policy

Description Inotuzumab ozogamicin (Besponsa ) is a CD22-directed antibody-drug conjugate.

POLICY AND PROCEDURE. SCOPE: Coordinated Care Health Plan (Plan) and Envolve Pharmacy Solution departments.

Clinical Policy: Suvorexant (Belsomra) Reference Number: CP.PMN.109 Effective Date: Last Review Date: Line of Business: HIM, Medicaid

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information.

Sexually Transmitted Disease Treatment Clinical Coverage Policy No: 1D-2 Provided in Health Departments Amended Date: October 1, 2015

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information.

Medically Unlikely Edits Policy

See Important Reminder at the end of this policy for important regulatory and legal information.

INTRODUCTION_final doc Revision Date: 1/1/2018 INTRODUCTION FOR NATIONAL CORRECT CODING INITIATIVE POLICY MANUAL FOR MEDICARE SERVICES

Global Days Policy, Professional

Contractor Information. LCD Information. FUTURE Local Coverage Determination (LCD): Frequency of Laboratory Tests (L35099) Document Information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information.

Rebundling and NCCI Editing

See Important Reminder at the end of this policy for important regulatory and legal information.

Description Carglumic acid is a synthetic structural analogue of N-acetylglutamate (NAG).

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information.

Clinical Policy: Hemin (Panhematin) Reference Number: CP.PHAR.181 Effective Date: Last Review Date: Line of Business: Medicaid

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information.

Medicare. Claim Review Programs: MR, NCCI Edits, MUEs, CERT, and RAC. Official CMS Information for Medicare Fee-For-Service Providers

National Correct Coding Initiative

Clinical Policy: Guselkumab (Tremfya) Reference Number: CP.PHAR.364 Effective Date: Last Review Date: 11.18

Clinical Policy: Ciclopirox (Penlac) Reference Number: CP.PMN.24 Effective Date: Last Review Date: Line of Business: Medicaid

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information.

IC Chapter 13. Provider Payment; General

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information.

Section: Administrative Subsection: None Date of Origin: 1/22/2004 Policy Number: RPM002 Last Updated: 1/6/2017 Last Reviewed: 1/18/2017

See Important Reminder at the end of this policy for important regulatory and legal information.

Clinical Policy: Etidronate (Didronel) Reference Number: CP.PMN.94 Effective Date: Last Review Date: 02.19

9/17/2018. Non-covered services. Description: Billing for services not covered under the Medicare program

See Important Reminder at the end of this policy for important regulatory and legal information.

Transcription:

Payment Policy: Clinical Validation of Modifer 25 Reference Number: CC.PP.013 Product Types: ALL Effective Date: 01/01/2013 Last Review Date: 02/24/2018 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Policy Overview The misuse of modifiers that override correct coding edits represents challenges for payors. Centene will institute a prepayment clinical claims review on all procedures billed with modifier -25. A registered nurse will review the information billed on the claim, along with the member and provider s claim history to determine whether or not it is likely that the modifier was used correctly for the circumstances of the patient on the date of service. The Health Plan, and its vendors, will use nationally published guidelines from CPT and CMS when determining whether or not the modifier was used correctly. Both CPT and CMS in the NCCI policy manual specify that by using a modifier 25 the provider is indicating that a significant, separately identifiable evaluation and management service (was provided) by the same physician on the same day of the procedure or other service. Additional CPT guidelines state that this significant and separable service must be above and beyond the other service provided or beyond the usual preoperative and postoperative care associated with the procedure that was performed. The NCCI policy manual states that If a procedure has a global period of 000 or 010 days, it is defined as a minor surgical procedure. (Osteopathic manipulative therapy and chiropractic manipulative therapy have global periods of 000.) The decision to perform a minor surgical procedure is included in the value of the minor surgical procedure and should not be reported separately as an E&M service. However, a significant and separately identifiable E&M service unrelated to the decision to perform the minor surgical procedure is separately reportable with modifier 25. The E&M service and minor surgical procedure do not require different diagnoses. If a minor surgical procedure is performed on a new patient, the same rules for reporting E&M services apply. The fact that the patient is new to the provider is not sufficient alone to justify reporting an E&M service on the same date of service as a minor surgical procedure. NCCI does contain some edits based on these principles, but the Medicare Carriers and A/B MACs processing practitioner service claims have separate edits. Reimbursement Claims Reimbursement Edit The Health Plan s clinical code auditing software will flag all provider claims billed with the modifier -25 for prepayment clinical validation. Clinical validation occurs prior to claims payment. Once a claim has been clinically validated, it is either released for payment or denied for incorrect use of the modifier. Page 1 of 5

Rationale for Edit should only be used to indicate that a significant, separately identifiable evaluation and management service (was provided) by the same physician on the same day of the procedure or other service. Pre-payment Clinical Claims review A significant, separately identifiable E/M service is defined or substantiated by documentation that satisfies the relevant criteria for the respective E/M service to be reported. If medical records do not indicate that significant, separately identifiable services were performed, Centene covers the primary procedure or other service, and denies the secondary E/M billed with Modifier 25. To avoid incorrect denials providers should assign all applicable diagnosis codes that indicate what the need for additional E/M services. Utilization Appeals/Reconsiderations In the event the claims documentation is insufficient to support billing modifier 25, the provider will receive a denial determination on their explanation of payment (EOP). The provider may submit an appeal or reconsideration request according to the guidelines outlined in the provider manual. Please submit all pertinent medical records for the date of service and procedures billed. Medical records should not be submitted on the first time claims submission as first time claim review consists only of a review of the information documented on the claim and in the member/provider history. Medical records should only be submitted once the provider receives a denial and wishes to request a reconsideration or appeal Documentation Requirements The following guidelines will be used to determine whether or not modifier 25 was used appropriately. If any one of the following conditions is met then reimbursement for the E/M service is recommended If the E/M service is the first time the provider has seen the patient or evaluated a major condition A diagnosis on the claim indicates that a separate medical condition was treated in addition to the procedure that was performed The patient s condition is worsening as evidenced by diagnostic procedures being performed on or around the date of services If a provider bills supplies or equipment, on or around the same date, that are unrelated to the procedure performed but would have required an E/M service to determine the patient s need Coding and Modifier Information This payment policy references Current Procedural Terminology (CPT ). CPT is a registered trademark of the American Medical Association. All CPT codes and descriptions are copyrighted 2017, American Medical Association. All rights reserved. CPT codes and CPT descriptions are from current manuals and those included herein are not intended to be allinclusive and are included for informational purposes only. Codes referenced in this payment Page 2 of 5

policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services. Modifier Descriptor -25 Significant, separately identifiable evaluation and management service by the same physician or other qualified health care professional on the same day of the procedure or other service Related Documents or Resources 1. Centers for Medicare and Medicaid Services, CMS Manual System and other CMS publications and services. 2. Centers for Medicare and Medicaid Services, National Correct Coding Initiative (NCCI) publications. 3. American Medical Association, Current Procedural Terminology (CPT ) and associated publications and services. References 1. Current Procedural Terminology (CPT ), 2017 2. HCPCS Level II, 2017 3. International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), 2017 4. ICD-10-CM Official Draft Code Set, 2017 Revision History 01/10/2017 Converted to corporate template and conducted annual review. 02/7/2017 Removed duplicate sentence in policy overview and made punctuation corrections. 02/24/2018 Update policy, updated resources, verified modifier, and conducted review. Important Reminder For the purposes of this payment policy, Health Plan means a health plan that has adopted this payment policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any other of such health plan s affiliates, as applicable. The purpose of this payment policy is to provide a guide to payment, which is a component of the guidelines used to assist in making coverage and payment determinations and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage and payment determinations and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, Page 3 of 5

certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable plan-level administrative policies and procedures. This payment policy is effective as of the date determined by Health Plan. The date of posting may not be the effective date of this payment policy. This payment policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this payment policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. Health Plan retains the right to change, amend or withdraw this payment policy, and additional payment policies may be developed and adopted as needed, at any time. This payment policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This payment policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions. Providers referred to in this policy are independent contractors who exercise independent judgment and over whom Health Plan has no control or right of control. Providers are not agents or employees of Health Plan. This payment policy is the property of Centene Corporation. Unauthorized copying, use, and distribution of this payment policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services. Note: For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this payment policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this payment policy. Note: For Medicare members, to ensure consistency with the Medicare National Coverage Determinations (NCD) and Local Coverage Determinations (LCD), all applicable NCDs and LCDs should be reviewed prior to applying the criteria set forth in this payment policy. Refer to the CMS website at http://www.cms.gov for additional information. 2018 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene and Centene Corporation are registered trademarks exclusively owned by Centene Corporation. Page 4 of 5

Page 5 of 5